METTL5

Summary

METTL5 (methyltransferase 5, N6-adenosine, HGNC:25006) is a protein-coding gene on chromosome 2q31.1, encoding rRNA N(6)-adenosine-methyltransferase METTL5 (Q9NRN9). Catalytic subunit of a heterodimer with TRMT112, which specifically methylates the 6th position of adenine in position 1832 of 18S rRNA.

Enables S-adenosyl-L-methionine binding activity and rRNA (adenine-N6-)-methyltransferase activity. Involved in positive regulation of translation and rRNA methylation. Located in several cellular components, including fibrillar center; postsynapse; and presynapse. Implicated in autosomal recessive intellectual developmental disorder 72.

Source: NCBI Gene 29081 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual developmental disorder, autosomal recessive 72 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 70 total — 4 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 17
• Druggable target: yes
• MANE Select transcript: NM_014168

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25006
Approved symbol	METTL5
Name	methyltransferase 5, N6-adenosine
Location	2q31.1
Locus type	gene with protein product
Status	Approved
Aliases	HSPC133
Ensembl gene	ENSG00000138382
Ensembl biotype	protein_coding
OMIM	618628
Entrez	29081

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000260953, ENST00000308099, ENST00000392640, ENST00000409340, ENST00000409837, ENST00000409965, ENST00000410097, ENST00000442181, ENST00000471560, ENST00000484351, ENST00000537825, ENST00000538491, ENST00000938651, ENST00000938652, ENST00000938653, ENST00000938654

RefSeq mRNA: 3 — MANE Select: NM_014168 NM_001293186, NM_001293187, NM_014168

CCDS: CCDS33320

Canonical transcript exons

ENST00000260953 — 7 exons

Exon	Start	End
ENSE00000882688	169821943	169822057
ENSE00001129808	169821092	169821273
ENSE00001466639	169824489	169824905
ENSE00001580434	169811757	169811858
ENSE00003510429	169812457	169812506
ENSE00003668398	169815477	169815528
ENSE00003687414	169819561	169819643

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 97.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.4120 / max 620.4743, expressed in 1814 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
31742	32.2349	1811
31741	1.0472	631
202465	0.1299	41

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	97.37	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.37	gold quality
biceps brachii	UBERON:0001507	97.33	gold quality
calcaneal tendon	UBERON:0003701	97.20	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.09	gold quality
vastus lateralis	UBERON:0001379	96.95	gold quality
islet of Langerhans	UBERON:0000006	96.81	gold quality
quadriceps femoris	UBERON:0001377	96.81	gold quality
heart right ventricle	UBERON:0002080	96.78	gold quality
palpebral conjunctiva	UBERON:0001812	96.56	gold quality
tendon	UBERON:0000043	96.55	gold quality
left coronary artery	UBERON:0001626	96.53	gold quality
right coronary artery	UBERON:0001625	96.47	gold quality
skin of hip	UBERON:0001554	96.33	gold quality
coronary artery	UBERON:0001621	96.25	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.25	gold quality
buccal mucosa cell	CL:0002336	96.24	gold quality
ascending aorta	UBERON:0001496	96.21	gold quality
thoracic aorta	UBERON:0001515	96.20	gold quality
tibial artery	UBERON:0007610	96.20	gold quality
aorta	UBERON:0000947	96.19	gold quality
artery	UBERON:0001637	96.19	gold quality
popliteal artery	UBERON:0002250	96.19	gold quality
renal glomerulus	UBERON:0000074	96.18	gold quality
descending thoracic aorta	UBERON:0002345	96.07	gold quality
body of tongue	UBERON:0011876	96.01	gold quality
deltoid	UBERON:0001476	95.96	gold quality
metanephric glomerulus	UBERON:0004736	95.96	gold quality
lower esophagus	UBERON:0013473	95.74	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.74	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	6.84
E-MTAB-6379	no	901.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 12)

• METTL5-TRMT112 partners act by extruding the adenosine to be modified from a double-stranded nucleic acid. (PMID:31328227)
• Ribosome 18S m(6)A Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth. (PMID:33357433)
• Enzymatic characterization of three human RNA adenosine methyltransferases reveals diverse substrate affinities and reaction optima. (PMID:33428944)
• Analysis of the role of METTL5 as a hub gene in lung adenocarcinoma based on a weighted gene co-expression network. (PMID:34517547)
• The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma. (PMID:35166644)
• Three Afghani siblings with a novel homozygous variant and further delineation of the clinical features of METTL5 related intellectual disability syndrome. (PMID:36305450)
• Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells. (PMID:36369791)
• METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. (PMID:36602428)
• The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression. (PMID:38613157)
• Biological significance of METTL5 in atherosclerosis: comprehensive analysis of single-cell and bulk RNA sequencing data. (PMID:38663914)
• METTL5: A Potential Biomarker for Nonsmall Cell Lung Cancer That Promotes Cancer Cell Proliferation by Interacting with IGF2BP3. (PMID:39023781)
• METTL5 enhances the mRNA stability of TPRKB through m[6]A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell. (PMID:39182664)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mettl5	ENSDARG00000068893
mus_musculus	Mettl5	ENSMUSG00000051730
rattus_norvegicus	Mettl5	ENSRNOG00000008469
drosophila_melanogaster	Mettl5	FBGN0036856
caenorhabditis_elegans		WBGENE00008008

Protein

Protein identifiers

rRNA N(6)-adenosine-methyltransferase METTL5 — Q9NRN9 (reviewed: Q9NRN9)

Alternative names: Methyltransferase-like protein 5

All UniProt accessions (8): B8ZZC8, B8ZZE3, B8ZZY8, E7EMN2, Q9NRN9, F5H4E8, H0YFV5, H7C0M7

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of a heterodimer with TRMT112, which specifically methylates the 6th position of adenine in position 1832 of 18S rRNA. N6-methylation of adenine(1832) in 18S rRNA resides in the decoding center of 18S rRNA and is required for translation and embryonic stem cells (ESCs) pluripotency and differentiation.

Subunit / interactions. Heterodimer; heterodimerizes with TRMT112.

Subcellular location. Nucleus. Presynapse. Postsynapse.

Tissue specificity. Expressed from very early development (8 post-conceptual weeks) and expression persists through adulthood in multiple substructures of the brain, including the cerebellar cortex, hippocampus, and striatum.

Disease relevance. Intellectual developmental disorder, autosomal recessive 72 (MRT72) [MIM:618665] A form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT72 patients manifest moderate to severe intellectual disability, microcephaly, and dysmorphic facial features. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. rRNA N6-adenosine-methyltransferase activity is inhibited by zinc.

Similarity. Belongs to the methyltransferase superfamily. PrmA family.

RefSeq proteins (3): NP_001280115, NP_001280116, NP_054887* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002052	DNA_methylase_N6_adenine_CS	Conserved_site
IPR007848	Small_mtfrase_dom	Domain
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily
IPR051720	rRNA_MeTrfase/Polyamine_Synth	Family

Pfam: PF05175

Catalyzed reactions (Rhea), 1 shown:

• adenosine(1832) in 18S rRNA + S-adenosyl-L-methionine = N(6)-methyladenosine(1832) in 18S rRNA + S-adenosyl-L-homocysteine + H(+) (RHEA:62612)

UniProt features (29 total): helix 8, strand 8, binding site 7, sequence variant 2, chain 1, mutagenesis site 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9OHL	X-RAY DIFFRACTION	1.29
6H2U	X-RAY DIFFRACTION	1.6
6H2V	X-RAY DIFFRACTION	2.49

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRN9-F1	92.36	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 28; 31; 59; 62; 64; 81; 108–109

Mutagenesis-validated functional residues (1):

Position	Phenotype
126–128	in mettl5-3a; abolished methyltransferase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 211 (showing top): GOBP_RIBOSOME_BIOGENESIS, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_RNA_METHYLATION, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_RNA_MODIFICATION, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_STEM_CELL_DIFFERENTIATION, ACEVEDO_LIVER_CANCER_UP, GOBP_RRNA_MODIFICATION, GOBP_METHYLATION, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GNF2_HAT1, GOBP_RRNA_METHYLATION, GRADE_COLON_AND_RECTAL_CANCER_UP

GO Biological Process (5): rRNA processing (GO:0006364), rRNA methylation (GO:0031167), positive regulation of translation (GO:0045727), stem cell differentiation (GO:0048863), methylation (GO:0032259)

GO Molecular Function (7): nucleic acid binding (GO:0003676), rRNA (adenine-N6-)-methyltransferase activity (GO:0008988), S-adenosyl-L-methionine binding (GO:1904047), protein binding (GO:0005515), methyltransferase activity (GO:0008168), S-adenosylmethionine-dependent methyltransferase activity (GO:0008757), transferase activity (GO:0016740)

GO Cellular Component (8): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleolus (GO:0005730), cytosol (GO:0005829), presynapse (GO:0098793), postsynapse (GO:0098794), cell projection (GO:0042995), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
binding	2
synapse	2
RNA processing	1
rRNA metabolic process	1
ribosome biogenesis	1
rRNA modification	1
RNA methylation	1
translation	1
regulation of translation	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
cell differentiation	1
metabolic process	1
N-methyltransferase activity	1
rRNA (adenine) methyltransferase activity	1
cation binding	1
sulfur compound binding	1
transferase activity, transferring one-carbon groups	1
methyltransferase activity	1
catalytic activity	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1
cell junction	1

Protein interactions and networks

STRING

1134 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
METTL5	TRMT112	Q9UI30	996
METTL5	ZCCHC4	Q9H5U6	969
METTL5	METTL16	Q86W50	951
METTL5	ZC3H13	Q5T200	924
METTL5	VIRMA	Q69YN4	895
METTL5	WTAP	Q15007	815
METTL5	METTL3	Q86U44	812
METTL5	RBM15	Q96T37	784
METTL5	METTL14	Q9HCE5	709
METTL5	CBLL1	Q75N03	670
METTL5	METTL15	A6NJ78	644
METTL5	TYW2	Q53H54	641
METTL5	BUD23	O43709	624
METTL5	METTL4	Q8N3J2	612
METTL5	HEMK2	Q9Y5N5	598

IntAct

13 interactions, top by confidence:

A	B	Type	Score
TRMT112	BUD23	psi-mi:“MI:0914”(association)	0.910
METTL5	TRMT112	psi-mi:“MI:0915”(physical association)	0.710
METTL5	TRMT112	psi-mi:“MI:0403”(colocalization)	0.710
ZBTB5	METTL5	psi-mi:“MI:0915”(physical association)	0.560
NTF3	HSPA5	psi-mi:“MI:0914”(association)	0.350
METTL5	ZBTB5	psi-mi:“MI:0915”(physical association)	0.000
METTL5	TRMT112	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): METTL5 (Co-fractionation), METTL5 (Affinity Capture-MS), ZBTB5 (Two-hybrid), TRMT112 (Two-hybrid), METTL5 (Affinity Capture-MS), USP5 (Affinity Capture-MS), FBXW7 (Affinity Capture-MS), FBXO32 (Affinity Capture-MS), SKP2 (Affinity Capture-MS), USP7 (Affinity Capture-MS), USP37 (Affinity Capture-MS), USP28 (Affinity Capture-MS), USP36 (Affinity Capture-MS), TRIM32 (Affinity Capture-MS), METTL5 (Proximity Label-MS)

ESM2 similar proteins: A6TRI3, A7N1I9, A7SE07, A7Z7T3, A8H551, A9KLV5, B0TSA1, B1HXA1, B4S0J8, B5FAT6, B5FE19, B6EGJ0, B6ELD3, B8F3G3, F1QVR8, O07635, O34522, P39199, P53384, P67502, P67503, Q03432, Q0SQX5, Q0TNA4, Q0WDE1, Q15TV2, Q18511, Q1WUP5, Q2FXG9, Q32DK7, Q3K307, Q3KQF0, Q5E3U5, Q5E5B4, Q5E7A8, Q5EB25, Q5I050, Q65G12, Q7MJ72, Q7MKX1

Diamond homologs: A0KNJ1, A0Q1R2, A1AGF9, A1KS36, A4WF74, A5I638, A5UD93, A5UIB7, A6LRN8, A6TES6, A7FDQ3, A7FXL3, A7GHH4, A7MXI3, A7ZSF3, A8A570, A8AQF7, A8GK75, A9MNA2, B0K3X8, B0KA79, B1ILM1, B1IQ33, B1JKF2, B1KZN5, B1LGM4, B1XHM8, B1XKZ0, B2K467, B2TM01, B2U2N5, B2V2I9, B2VL75, B3PBH5, B4EX23, B4SUN8, B4TJV7, B4TX91, B5BGT7, B5F7P3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
METTL5	“form complex”	“METTL5-TRM112 methyltransferase complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	3
Uncertain significance	38
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (7)

Variant ID	HGVS	Classification
1685946	NM_014168.4(METTL5):c.591+2T>G	Pathogenic
3064180	NM_014168.4(METTL5):c.224+1G>A	Pathogenic
3391100	NM_014168.4(METTL5):c.542-1G>T	Pathogenic
689379	NM_014168.4(METTL5):c.344_345del (p.Arg115fs)	Pathogenic
1804912	NM_014168.4(METTL5):c.406+1_406+2insATACAAATTC	Likely pathogenic
3065390	NM_014168.4(METTL5):c.225-1G>T	Likely pathogenic
3393292	NM_014168.4(METTL5):c.196dup (p.Ser66fs)	Likely pathogenic

SpliceAI

1338 predictions. Top by Δscore:

Variant	Effect	Δscore
2:169810281:A:AG	acceptor_gain	1.0000
2:169810282:G:GG	acceptor_gain	1.0000
2:169810282:GA:G	acceptor_gain	1.0000
2:169810282:GAA:G	acceptor_gain	1.0000
2:169810850:T:TA	acceptor_gain	1.0000
2:169810855:TA:T	acceptor_loss	1.0000
2:169810856:AGG:A	acceptor_gain	1.0000
2:169810857:G:GG	acceptor_loss	1.0000
2:169810857:GGG:G	acceptor_gain	1.0000
2:169811034:G:GT	donor_gain	1.0000
2:169811034:G:T	donor_gain	1.0000
2:169811038:TCAAA:T	donor_gain	1.0000
2:169811180:CAGGT:C	acceptor_loss	1.0000
2:169811181:A:AC	acceptor_loss	1.0000
2:169811182:G:A	acceptor_loss	1.0000
2:169811324:G:T	donor_loss	1.0000
2:169811325:T:A	donor_loss	1.0000
2:169812455:A:AC	donor_gain	1.0000
2:169812456:C:CC	donor_gain	1.0000
2:169819554:AACTT:A	donor_loss	1.0000
2:169819555:ACTT:A	donor_loss	1.0000
2:169819556:CTTA:C	donor_loss	1.0000
2:169819557:TT:T	donor_loss	1.0000
2:169819558:TAC:T	donor_loss	1.0000
2:169819559:A:AC	donor_gain	1.0000
2:169819559:A:C	donor_loss	1.0000
2:169819560:C:CT	donor_gain	1.0000
2:169819560:CTT:C	donor_gain	1.0000
2:169819560:CTTCT:C	donor_gain	1.0000
2:169821939:GTAC:G	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000062870 (2:169812221 T>C), RS1000117530 (2:169818871 C>T), RS1000226919 (2:169819307 CTT>C), RS1000350487 (2:169824868 C>T), RS1000399055 (2:169812515 C>T), RS1000532045 (2:169817460 T>C,G), RS1000693855 (2:169823833 T>C), RS1000795540 (2:169821823 T>A), RS1001127240 (2:169824026 A>G), RS1001168861 (2:169818222 A>G), RS1001306882 (2:169811411 G>A,T), RS1001383600 (2:169826175 G>GT), RS1001620275 (2:169818623 T>A), RS1001634843 (2:169820938 C>T), RS1001982902 (2:169823140 C>A)

Disease associations

OMIM: gene MIM:618628 | disease phenotypes: MIM:618665

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual developmental disorder, autosomal recessive 72	Strong	Autosomal recessive
autosomal recessive primary microcephaly	Supportive	Autosomal recessive

Mondo (2): intellectual developmental disorder, autosomal recessive 72 (MONDO:0032860), autosomal recessive primary microcephaly (MONDO:0016660)

Orphanet (0):

HPO phenotypes

17 total (17 of 17 shown, HPO-id order):

HPO	Term
HP:0000076	Vesicoureteral reflux
HP:0000122	Unilateral renal agenesis
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000340	Sloping forehead
HP:0000582	Upslanted palpebral fissure
HP:0001263	Global developmental delay
HP:0001274	Agenesis of corpus callosum
HP:0001302	Pachygyria
HP:0001347	Hyperreflexia
HP:0001510	Growth delay
HP:0002119	Ventriculomegaly
HP:0002282	Gray matter heterotopia
HP:0003103	Abnormal cortical bone morphology
HP:0004322	Short stature
HP:0007333	Hypoplasia of the frontal lobes
HP:0010864	Severe intellectual disability

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009190_3	Medial orbital frontal cortex volume	7.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C579935	Autosomal Recessive Primary Microcephaly (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5483089 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Lead	affects splicing, increases expression	2
Tretinoin	decreases expression	2
Valproic Acid	affects expression, increases methylation	2
aristolochic acid I	decreases expression	1
bisphenol A	affects expression	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
beta-methylcholine	affects expression	1
chloropicrin	increases expression	1
jinfukang	decreases expression	1
Acetaminophen	decreases expression	1
Ethanol	increases abundance, affects cotreatment, decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	increases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methyl Methanesulfonate	decreases expression	1
Ozone	increases abundance, affects expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Potassium Dichromate	decreases expression	1
Quercetin	decreases expression	1
Smoke	decreases expression, increases abundance	1
Thiram	decreases expression	1
Cyclosporine	increases expression	1
Sodium Selenite	increases expression	1
Particulate Matter	affects cotreatment, decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5317819	Binding	Inhibition of human METTL5/TRM112 using 5’-UCG UAA CAA GGU UU-3’ as substrate and SAM as cosubstrate at 10 uM incubated for 1 hr	Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence. — J Med Chem

Cellosaurus cell lines

8 cell lines: 5 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A4D1	SEES3-1V human METTL5, clone1	Embryonic stem cell	Male
CVCL_A4D2	SEES3-1V human METTL5, clone2	Embryonic stem cell	Male
CVCL_A4D3	SEES3-1V human METTL5, clone3	Embryonic stem cell	Male
CVCL_B1X1	Abcam HeLa METTL5 KO	Cancer cell line	Female
CVCL_SY05	HAP1 METTL5 (-) 1	Cancer cell line	Male
CVCL_SY06	HAP1 METTL5 (-) 2	Cancer cell line	Male
CVCL_SY07	HAP1 METTL5 (-) 3	Cancer cell line	Male
CVCL_SY08	HAP1 METTL5 (-) 5	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.